How reclassifying marijuana under federal law benefits New York businesses, patients

Businesses preparing to invest millions of dollars in New York’s fledgling medical marijuana industry are betting the ever-present risk of federal agents shutting them down disappears in the near future.

They received help this week when a doctors’ group urged federal lawmakers to reclassify the drug.

The American Academy of Pediatrics released a report that promoted changing marijuana from a Drug Enforcement Administration schedule I to a schedule II drug.